Literature DB >> 24284322

Nucleophosmin contributes to the transcriptional activation function of the Epstein-Barr virus EBNA1 protein.

Natasha Malik-Soni1, Lori Frappier.   

Abstract

The Epstein-Barr virus (EBV) EBNA1 protein plays important roles in latent infection, including transcriptional activation of EBV latency genes by binding to the family-of-repeats (FR) element. Through a proteomic approach, we previously identified an interaction between EBNA1 and the histone chaperone nucleophosmin. Here we show that the EBNA1-nucleophosmin interaction is direct and requires the Gly-Arg-rich sequences that contribute to transactivation. Additionally, nucleophosmin is recruited by EBNA1 to the FR element and is required for EBNA1-mediated transcriptional activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24284322      PMCID: PMC3911533          DOI: 10.1128/JVI.02521-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus.

Authors:  D F Ceccarelli; L Frappier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function.

Authors:  Michal-Ruth Schweiger; Jianxin You; Peter M Howley
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA.

Authors:  Bo Huang; Xiao-Dong Yang; Ming-Ming Zhou; Keiko Ozato; Lin-Feng Chen
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

5.  The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication.

Authors:  W H Huang; B Y Yung; W J Syu; Y H Lee
Journal:  J Biol Chem       Date:  2001-04-17       Impact factor: 5.157

6.  Nucleophosmin is required for DNA integrity and p19Arf protein stability.

Authors:  Emanuela Colombo; Paola Bonetti; Eros Lazzerini Denchi; Paola Martinelli; Raffaella Zamponi; Jean-Christophe Marine; Kristian Helin; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  The EBNA1 protein of Epstein-Barr virus functionally interacts with Brd4.

Authors:  Ammy Lin; Shan Wang; Tin Nguyen; Kathy Shire; Lori Frappier
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

8.  Nucleophosmin regulates the stability and transcriptional activity of p53.

Authors:  Emanuela Colombo; Jean-Christophe Marine; Davide Danovi; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Nat Cell Biol       Date:  2002-07       Impact factor: 28.824

9.  Nucleosome assembly proteins bind to Epstein-Barr virus nuclear antigen 1 and affect its functions in DNA replication and transcriptional activation.

Authors:  Shan Wang; Lori Frappier
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

10.  The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.

Authors:  Cheng-Der Liu; Ya-Lin Chen; Yi-Li Min; Bo Zhao; Chi-Ping Cheng; Myung-Soo Kang; Shu-Jun Chiu; Elliott Kieff; Chih-Wen Peng
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

View more
  8 in total

1.  Morphological, Biochemical, and Functional Study of Viral Replication Compartments Isolated from Adenovirus-Infected Cells.

Authors:  Paloma Hidalgo; Lourdes Anzures; Armando Hernández-Mendoza; Adán Guerrero; Christopher D Wood; Margarita Valdés; Thomas Dobner; Ramón A Gonzalez
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

2.  Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.

Authors:  Sheila Mansouri; Qun Pan; Benjamin J Blencowe; Julie M Claycomb; Lori Frappier
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

3.  A proteomic approach to discover and compare interacting partners of papillomavirus E2 proteins from diverse phylogenetic groups.

Authors:  Moon Kyoo Jang; D Eric Anderson; Koenraad van Doorslaer; Alison A McBride
Journal:  Proteomics       Date:  2015-04-28       Impact factor: 3.984

4.  Ribosome Protein L4 is essential for Epstein-Barr Virus Nuclear Antigen 1 function.

Authors:  Chih-Lung Shen; Cheng-Der Liu; Ren-In You; Yung-Hao Ching; Jun Liang; Liangru Ke; Ya-Lin Chen; Hong-Chi Chen; Hao-Jen Hsu; Je-Wen Liou; Elliott Kieff; Chih-Wen Peng
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

Review 5.  Epstein-Barr virus latent genes.

Authors:  Myung-Soo Kang; Elliott Kieff
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

6.  Biophysical Characterization of Nucleophosmin Interactions with Human Immunodeficiency Virus Rev and Herpes Simplex Virus US11.

Authors:  Kazem Nouri; Jens M Moll; Lech-Gustav Milroy; Anika Hain; Radovan Dvorsky; Ehsan Amin; Michael Lenders; Luitgard Nagel-Steger; Sebastian Howe; Sander H J Smits; Hartmut Hengel; Lutz Schmitt; Carsten Münk; Luc Brunsveld; Mohammad R Ahmadian
Journal:  PLoS One       Date:  2015-12-01       Impact factor: 3.240

Review 7.  EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.

Authors:  Lijun Jiang; Chen Xie; Hong Lok Lung; Kwok Wai Lo; Ga-Lai Law; Nai-Ki Mak; Ka-Leung Wong
Journal:  Theranostics       Date:  2018-10-22       Impact factor: 11.556

Review 8.  EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers.

Authors:  Joanna B Wilson; Evelyne Manet; Henri Gruffat; Pierre Busson; Marc Blondel; Robin Fahraeus
Journal:  Cancers (Basel)       Date:  2018-04-06       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.